| Drug Name |
Mephenytoin |
| Drug ID |
BADD_D01386 |
| Description |
Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin. Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. Mephenytoin and oxazolidinedione derivatives are associated with higher incidences of blood dyscrasias compared to other anticonvulsants. |
| Indications and Usage |
For the treatment of refractory partial epilepsy. |
| Marketing Status |
approved; investigational; withdrawn |
| ATC Code |
N03AB04 |
| DrugBank ID |
DB00532
|
| KEGG ID |
D00375
|
| MeSH ID |
D008617
|
| PubChem ID |
4060
|
| TTD Drug ID |
D07RGW
|
| NDC Product Code |
Not Available |
| UNII |
R420KW629U
|
| Synonyms |
Mephenytoin | 5-Ethyl-3-Methyl-5-Phenylhydantoin | 5 Ethyl 3 Methyl 5 Phenylhydantoin | Mefenetoin | Methoin | Methyl Phenetoin | Phenetoin, Methyl | Phenantoin | Mesantoin |
